Literature DB >> 8468558

Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans.

A L Erickson1, C M Walker.   

Abstract

Cytotoxic T lymphocyte (CTL) responses to vaccinia virus (VV) were studied in human subjects receiving smallpox vaccine by dermal scarification. After in vitro restimulation with VV, peripheral blood mononuclear cells (PBMCs) from three of six vaccinated subjects killed virus-infected target cells. VV-specific, HLA-restricted CTL activity was mediated primarily by CD8+ cells, although low levels of lytic activity by CD4+ cells were observed in some experiments. Two of the three responders had no history of exposure to VV prior to vaccination, whereas all three non-responders were vaccinated against smallpox during childhood. PBMCs from an additional three subjects who had received smallpox vaccine at least 20 years previously were negative for CTL activity. These data suggest that the duration of memory CTL populations against VV in the peripheral blood is limited, and that pre-existing immunity to VV may interfere with boosting of the CTL response upon revaccination.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8468558     DOI: 10.1099/0022-1317-74-4-751

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

Authors:  J C Ramírez; M M Gherardi; D Rodríguez; M Esteban
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

3.  On the role of antigen in maintaining cytotoxic T-cell memory.

Authors:  T M Kündig; M F Bachmann; S Oehen; U W Hoffmann; J J Simard; C P Kalberer; H Pircher; P S Ohashi; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

4.  Cell-mediated immune responses of lambs to challenge with bovine respiratory syncytial virus.

Authors:  A K Sharma; Z Woldehiwet
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.

Authors:  Kenneth L Johnson; Inna G Ovsyannikova; Christopher J Mason; H Robert Bergen; Gregory A Poland
Journal:  Vaccine       Date:  2009-10-12       Impact factor: 3.641

6.  A novel, killed-virus nasal vaccinia virus vaccine.

Authors:  Anna U Bielinska; Alexander A Chepurnov; Jeffrey J Landers; Katarzyna W Janczak; Tatiana S Chepurnova; Gary D Luker; James R Baker
Journal:  Clin Vaccine Immunol       Date:  2007-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.